How do I buy Omeros Corporation (OMER) stock?

Buying Omeros Corporation (OMER) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "OMER", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy OMER by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for OMER on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Omeros Corporation from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Omeros Corporation (OMER) pay dividends?

At the moment, Omeros Corporation (OMER) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track OMER's performance via the price chart in the Gotrade app.

Is buying OMER on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy OMER?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if OMER is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Omeros Corporation (OMER) Stock Price: Nov 11 Close $18.15

Latest news

Stocktwits

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

OMEROctober 16, 2026

Stocktwits

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

OMER

Stocktwits

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

OMEROctober 16, 2026

Stocktwits

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

OMER

Business Wire

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

NeutralOMEROctober 16, 2026

Business WireNeutral

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

OMER

Stocktwits

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

OMERSeptember 22, 2026

Stocktwits

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

OMER

Zacks Investment Research

Dow, Nasdaq, S&P 500 Futures: How Markets Are Trading After July CPI As More Inflation Data Looms

OMERAugust 13, 2026

Stocktwits

Dow, Nasdaq, S&P 500 Futures: How Markets Are Trading After July CPI As More Inflation Data Looms

OMER

MarketBeat

Omeros Q2 Earnings Call Highlights

OMERAugust 13, 2026

MarketBeat

Omeros Q2 Earnings Call Highlights

OMER

Zacks Investment Research

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

OMERAugust 12, 2026

Zacks Investment Research

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

OMER

News tone: automated (AI) classification of the article's content, not a price prediction.

About Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

SectorHealthcare

IndustryBiotechnology

Employees175

CEODr. Gregory A. Demopulos M.D.

IPO DateOct 8, 2009

HeadquartersSeattle, WA

Key Executives

Name	Title	Year Born
Dr. Gregory A. Demopulos M.D.	Co-Founder, Chairman, CEO & President	1959
Mr. David J. Borges	VP of Finance, Chief Accounting Officer & Treasurer	1965
Mr. Peter B. Cancelmo J.D.	VP, General Counsel & Corporate Secretary	1979
Dr. Pamela Pierce Palmer M.D., Ph.D.	Co-Founder	1963
Dr. George A. Gaitanaris M.D., Ph.D.	Chief Scientific Officer & VP of Science	1957
Mr. Peter W. Williams	Vice President of Human Resources	1968
Dr. Catherine A. Melfi Ph.D.	Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems	1959
Mr. David W. Ghesquiere	VP & Chief Business Development Officer	1967
William E. Woodman	VP & Chief Commercial Officer	—

Fundamentals

Valuation

Price-to-sales ratio32.59

Price-to-book value-24.39

PEG ratio0.81

Profitability

Return on Equity-109.00%

Return on Assets46.00%

Return on Sales353.00%

Gross margin (latest quarter)97.20%

EBITDA$136.68M

Trading

Average volume1,140,296

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 52.53
MACD 12/26/9: -0.12
EMA 9 of MACD: -0.16
MACD histogram: 0.04
SMA 50: $18.32; Price below SMA 50
EMA 50: $17.53; Price above EMA 50
SMA 200: $13.71; Price above SMA 200
EMA 200: $14.44; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

1 analyst rating

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $22.00
Average: $22.00
High: $22.00

Cantor Fitzgerald

Olivia Brayer Saunders

Buy

Target price

$22.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-13.1	-5.7
2022	-14.2	+12.5	-15.4	-42.5	-26.4	+13.6	+7.3	-10.4	-27.8	-5.2	-35.9	+7.6
2023	+16.9	+30.9	+31.4	+25.5	+9.5	-25.3	-17.1	-17.0	-17.5	-57.0	+93.8	+46.6
2024	-1.5	+32.4	-27.8	-1.3	-1.2	+0.0	+36.5	-16.1	+0.0	+5.8	+178.2	-17.3
2025	-12.4	-0.2	+0.6	-7.1	-56.0	-2.6	+30.3	+15.2	-4.4	+77.1	+35.1	+77.5
2026	-28.6	+2.8	-11.9	+20.9	-26.7	-11.3	+25.8	+49.6	+1.5	-0.2	+1.8

Compare stocks

OMER

Buy OMER

Market cap

$1.31B

-

Price / Earnings ratio

10.00

-

Price / Sales ratio

32.59

-

Dividend yield

0.00%

-

Average volume

1,140,296

-

Earnings per share

$1.91

-

Omeros Corporation (OMER) Stock

Key stats

Compare with OMER

Recent news

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Dow, Nasdaq, S&P 500 Futures: How Markets Are Trading After July CPI As More Inflation Data Looms

Dow, Nasdaq, S&P 500 Futures: How Markets Are Trading After July CPI As More Inflation Data Looms

Omeros Q2 Earnings Call Highlights

Omeros Q2 Earnings Call Highlights

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

About Omeros Corporation

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade